Berapa harga Bio-Path Holdings, Inc. (BPTH)

Harga Bio-Path Holdings, Inc. (BPTH) adalah $0.035

Apa kapitalisasi pasar Bio-Path Holdings, Inc. (BPTH)

Kapitalisasi pasar Bio-Path Holdings, Inc. (BPTH) adalah $326.98K

Pendapatan Bio-Path Holdings, Inc. (BPTH)

Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.

Tahun	Pendapatan	Mengubah
Tidak cukup data untuk tanggal yang disediakan.

Tahun

Pendapatan

Mengubah

Tidak cukup data untuk tanggal yang disediakan.

Perusahaan	Pendapatan	Perbedaan Pendapatan	Negara
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$10.11B	-	BE

Perusahaan

Pendapatan

Perbedaan Pendapatan

Negara